Cerebral syndrome with cognitive impairment in chronic cerebral ischemia and its correction by agomelatine

Efficiency of the drug Agomelatine (25 mg at bedtime 8 weeks) employed in treating patients suffering from chronic cerebral ischemia of the I and II stages (n = 33) is evaluated. Assessments were made against the background of essential hypertension of the II stage with the risk of the II degree (stable progress of the disease under rational combinations of antihypertensive medications). Complaints of cerebral and cognitive nature were registered. In the course of treatment, mild cognitive impairments with symptoms of depression and anxiety disorders from mild to moderate levels were registered. It was found out that agomelatine improves sleep quality (75,8 %) and reduces frequency of periodic headache complaints. The headaches have diffuse character and are associated with emotional oг physical stress (30 %). The drag also diminishes non-systemic dizziness and unsteadiness when walking (21,6 %), lessens fatigue and a feeling of general discomfort (18 %) (p